TERRI FLEMING: Open Payments
NPI 1265916746 · NORWALK, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,199 in 80 payments from 10 companies in 2025. Trend: 2023 $18 · 2024 $0 · 2025 $1,199
Food & beverage: $1,199
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 40 | $478 |
| Otsuka America Pharmaceutical, Inc. | 14 | $219 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $200 |
| Alkermes, Inc. | 8 | $136 |
| Janssen Pharmaceuticals, Inc | 3 | $51 |
| Braeburn Inc. | 2 | $45 |
| Indivior Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| ABBVIE INC. | 1 | $17 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
Products named: INGREZZA, CAPLYTA, REXULTI, ARISTADA, INVEGA SUSTENNA, BRIXADI, VIVITROL, ABILIFY MAINTENA.
Industry payments across CT — which companies pay providers there.
